R49
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 6
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- INTERFERON_GAMMA_RESPONSE+0.530
- ALLOGRAFT_REJECTION+0.440
- IL6_JAK_STAT3_SIGNALING+0.410
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.230
- IL2_STAT5_SIGNALING+0.210
- COMPLEMENT+0.200
- BILE_ACID_METABOLISM+0.180
- NOTCH_SIGNALING+0.180
Top 10 suppressed
- MYC_TARGETS_V1-0.440
- TGF_BETA_SIGNALING-0.360
- ANDROGEN_RESPONSE-0.350
- G2M_CHECKPOINT-0.350
- UV_RESPONSE_DN-0.340
- MYC_TARGETS_V2-0.320
- MITOTIC_SPINDLE-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- E2F_TARGETS-0.240
- HYPOXIA-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-S3-AA17-01A-11R-A41B-07 | — | D | 0.861 |
| 2 | SRR2778078 | — | — | 0.858 |
| 3 | R238 | — | — | 0.849 |
| 4 | MNG443 | — | — | 0.847 |
| 5 | 5566453e-df41-4aab-8dd0-825efbece954 | — | — | 0.832 |
| 6 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.818 |
| 7 | SRR25617853 | — | D | 0.814 |
| 8 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.812 |
| 9 | R13 | — | — | 0.810 |
| 10 | R243 | — | — | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |